Publications by authors named "Maria Paricek"
Article Synopsis
- The RTS,S/AS01(E) malaria vaccine is being evaluated for infant immunization in Africa, with a study extending follow-up to 19 months to assess safety and efficacy.
- A randomized phase 2 trial involved 511 children in Ghana, Tanzania, and Gabon, comparing different vaccine schedules alongside standard immunizations.
- Results showed higher immune responses in RTS,S/AS01(E) groups compared to controls, with no serious adverse events linked to the vaccine, indicating its potential for safe and effective use in malaria prevention.
Background: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI).
Methods: This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01(E) when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01(E) at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01(E) at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only.